Jason B. Fleming
YOU?
Author Swipe
View article: Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma
Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma Open
GDF-15 may be a potential biomarker for "pre-cachexia" in the non-Hispanic White and the Hispanic population, but not non-Hispanic Black individuals. These findings underscore the unmet need to enroll non-Hispanic Black participants in cli…
View article: Supplementary Figure S7 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S7 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Sensitivity analysis scatterplots of tSMA and pSMA.
View article: Supplementary Figure S4 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S4 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Changes in tSMA and pSMA by clinicodemographic covariates bar charts.
View article: Supplementary Table S3 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Table S3 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Mean total skeletal muscle area (tSMA) and psoas skeletal muscle area (pSMA) at diagnosis and follow-up among PDAC cohort participants overall and according to edema status.
View article: Supplementary Table S2 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Select clinical and epidemiological characteristics of the study population of all PDAC patients in the FPC Cohort and according to those included versus excluded in the current analysis.
View article: Supplementary Table S4 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Table S4 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Adjusted mean change in total skeletal muscle area (tSMA) and psoas skeletal muscle area (pSMA) at L3 with pairwise comparisons by edema status.
View article: Supplementary Figure S5 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S5 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Forest plots of tSMA and pSMA changes and mortality.
View article: Supplementary Figure S3 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S3 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Directed acyclic graph for Cox proportional hazards regression. Directed acyclic graph representing all variables considered in building multivariable models for the Cox proportional hazards regression representing the associations of musc…
View article: Data from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Data from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Background:Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no stu…
View article: Supplementary Table S5 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Table S5 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Adjusted mean change in total skeletal muscle area (tSMA) and psoas skeletal muscle area (pSMA) by clinically relevant covariables in subgroups by edema status.
View article: Supplementary Figure S1 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S1 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Inclusion and exclusion criteria flow chart.
View article: Supplementary Figure S2 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S2 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Directed acyclic graph for generalized linear model. Directed acyclic graph representing all variables considered in building multivariable models for the generalized linear models representing the associations of PDAC diagnosis with post-…
View article: Supplementary Figure S6 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Figure S6 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Sensitivity analysis changes in tSMA and pSMA bar charts.
View article: Supplementary Table S1 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma Open
Results of the change-in-estimate assessment of confounding.
View article: Data from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Data from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and …
View article: Supplementary Table 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Table 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Transcriptomic and secretome analysis of Smad4 WT and Smad4-deficient PDAC cells
View article: Supplementary Figure 6 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 6 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Inhibition of TGFb reduces IL-6 expression and STAT3 activation in PDAC
View article: Supplementary Figure 3 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 3 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Generation of orthotopic mouse models of Smad4 mutant pancreatic cancer
View article: Supplementary Figure 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 1 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
TGFb gene family LOH and SMAD mosaicism
View article: Supplementary Figure 4 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 4 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Loss of Smad4 alters the transcriptome of pancreatic cancer cells
View article: Supplementary Figure 7 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 7 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Inhibition of TGFb reduces survival in mice bearing 6620c1 orthotopic tumors
View article: Supplementary Figure 5 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 5 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Loss of Smad4 alters the secretome of pancreatic cancer cells
View article: Supplementary Figure 2 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Supplementary Figure 2 from SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
Immune landscape of SMAD4 WT and mutant human PDA
View article: Comparing Care Delivery Efficiency Between Emergency Department and Oncology Urgent Care
Comparing Care Delivery Efficiency Between Emergency Department and Oncology Urgent Care Open
Future work should more broadly investigate care delivery at each site, including the cost of care.
View article: Lymphatic mapping Of Oropharyngeal Cancer (LOOC): protocol for a phase II surgical imaging trial to evaluate contralateral drainage and occult metastasis in oropharyngeal cancer
Lymphatic mapping Of Oropharyngeal Cancer (LOOC): protocol for a phase II surgical imaging trial to evaluate contralateral drainage and occult metastasis in oropharyngeal cancer Open
Introduction Treatment of the node negative contralateral neck in oropharyngeal cancer (OPC) remains debated, with no clear consensus. Prophylactic contralateral neck treatment (either surgically or via irradiation) is generally recommende…
View article: SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition Open
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and …
View article: Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy
Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy Open
Background: In patients with curatively resected pancreatic adenocarcinoma who have undergone neoadjuvant chemotherapy (NACT), evidence supporting the benefit of additional adjuvant chemotherapy (ACT) remains limited. We aim to identify fa…
View article: Supplementary Figure 8 from Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles
Supplementary Figure 8 from Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles Open
Mutation frequency for KNCN and TMEM184B in 597 colorectal cancer patients by ethnicity
View article: Supplementary Table 14 from Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles
Supplementary Table 14 from Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles Open
Supplementary Table 14 shows associations between global genetic ancestry and tumor mutational signatures in 718 colorectal cancer patients